Minervini F, Algaron F, Rizzello C G, Fox P F, Monnet V, Gobbetti M
Dipartimento di Protezione delle Piante e Microbiologia Applicata, Facoltà di Agraria, Università degli Studi di Bari, Italy.
Appl Environ Microbiol. 2003 Sep;69(9):5297-305. doi: 10.1128/AEM.69.9.5297-5305.2003.
Sodium caseinates prepared from bovine, sheep, goat, pig, buffalo or human milk were hydrolyzed by a partially purified proteinase of Lactobacillus helveticus PR4. Peptides in each hydrolysate were fractionated by reversed-phase fast-protein liquid chromatography. The fractions which showed the highest angiotensin I-converting-enzyme (ACE)-inhibitory or antibacterial activity were sequenced by mass spectrum and Edman degradation analyses. Various ACE-inhibitory peptides were found in the hydrolysates: the bovine alpha(S1)-casein (alpha(S1)-CN) 24-47 fragment (f24-47), f169-193, and beta-CN f58-76; ovine alpha(S1)-CN f1-6 and alpha(S2)-CN f182-185 and f186-188; caprine beta-CN f58-65 and alpha(S2)-CN f182-187; buffalo beta-CN f58-66; and a mixture of three tripeptides originating from human beta-CN. A mixture of peptides with a C-terminal sequence, Pro-Gly-Pro, was found in the most active fraction of the pig sodium caseinate hydrolysate. The highest ACE-inhibitory activity of some peptides corresponded to the concentration of the ACE inhibitor (S)-N-(1-[ethoxycarbonyl]-3-phenylpropyl)-ala-pro maleate (enalapril) of 49.253 micro g/ml (100 micro mol/liter). Several of the above sequences had features in common with other ACE-inhibitory peptides reported in the literature. The 50% inhibitory concentration (IC(50)) of some of the crude peptide fractions was very low (16 to 100 micro g/ml). Some identified peptides were chemically synthesized, and the ACE-inhibitory activity and IC(50)s were confirmed. An antibacterial peptide corresponding to beta-CN f184-210 was identified in human sodium caseinate hydrolysate. It showed a very large spectrum of inhibition against gram-positive and -negative bacteria, including species of potential clinical interest, such as Enterococcus faecium, Bacillus megaterium, Escherichia coli, Listeria innocua, Salmonella spp., Yersinia enterocolitica, and Staphylococcus aureus. The MIC for E. coli F19 was ca. 50 micro g/ml. Once generated, the bioactive peptides were resistant to further degradation by proteinase of L. helveticus PR4 or by trypsin and chymotrypsin.
用瑞士乳杆菌PR4的部分纯化蛋白酶水解由牛乳、羊乳、山羊乳、猪乳、水牛乳或人乳制备的酪蛋白酸钠。通过反相快速蛋白质液相色谱法对每种水解产物中的肽进行分级分离。通过质谱和埃德曼降解分析对显示出最高血管紧张素I转换酶(ACE)抑制活性或抗菌活性的级分进行测序。在水解产物中发现了多种ACE抑制肽:牛α(S1)-酪蛋白(α(S1)-CN)24-47片段(f24-47)、f169-193和β-CN f58-76;绵羊α(S1)-CN f1-6和α(S2)-CN f182-185以及f186-188;山羊β-CN f58-65和α(S2)-CN f182-187;水牛β-CN f58-66;以及源自人β-CN的三种三肽的混合物。在猪酪蛋白酸钠水解产物的最活性级分中发现了具有C末端序列Pro-Gly-Pro的肽混合物。一些肽的最高ACE抑制活性相当于ACE抑制剂(S)-N-(1-[乙氧羰基]-3-苯丙基)-丙氨酸-脯氨酸马来酸盐(依那普利)浓度为49.253μg/ml(100μmol/升)。上述几个序列与文献中报道的其他ACE抑制肽有共同特征。一些粗肽级分的50%抑制浓度(IC50)非常低(16至100μg/ml)。对一些鉴定出的肽进行了化学合成,并确认了其ACE抑制活性和IC50。在人酪蛋白酸钠水解产物中鉴定出一种对应于β-CN f184-210的抗菌肽。它对革兰氏阳性和阴性细菌显示出非常广泛的抑制谱,包括具有潜在临床意义的菌种,如粪肠球菌、巨大芽孢杆菌、大肠杆菌、无害李斯特菌、沙门氏菌属、小肠结肠炎耶尔森菌和金黄色葡萄球菌。对大肠杆菌F19的最低抑菌浓度约为50μg/ml。一旦产生,这些生物活性肽对瑞士乳杆菌PR4的蛋白酶或胰蛋白酶和糜蛋白酶的进一步降解具有抗性。